Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease.
OBJECTIVE
Plasma citrulline, a nonprotein amino acid produced by enterocytes, was suggested as a marker of remnant enterocyte mass in patients with short bowel. Our objective was to evaluate citrulline as a marker of severity and extent of villous atrophy in patients without intestinal resection.


METHODS
Forty-two patients with celiac disease and 10 patients with non-celiac villous atrophy disease were studied by plasma postabsorptive citrulline and biological dosages, biopsies of proximal (duodenojejunal) small bowel and distal ileum (n = 25), or measurement of vitamin B(12) absorption (n = 4). Nine patients were reevaluated after following a gluten-free diet for 1 year. Controls were 51 healthy subjects and 10 severely malnourished patients with anorexia nervosa with no intestinal mucosal abnormalities.


RESULTS
Plasma citrulline concentration was lower (P < 0.001) in patients with villous atrophy (24 +/- 13 micromol/L) than in healthy subjects (40 +/- 10 micromol/L) and patients with anorexia nervosa (39 +/- 9 micromol/L). Three thresholds were individualized: <10 micromol/L for patients with diffuse total villous atrophy (n = 10), 10-20 micromol/L for patients with proximal-only total villous atrophy (n = 12), and 20-30 micromol/L for patients with partial villous atrophy (n = 10). Plasma citrulline concentration was correlated to the severity and extent of villous atrophy (r = 0.81; P < 0.001) and to albuminemia (r = 0.47; P < 0.01). Receiver operating characteristic curves indicated that plasma citrulline concentration was the best biological variable to predict villous atrophy. Following a 1-year gluten-free diet, plasma citrulline concentration increased in histologically responsive (n = 6) but not in unresponsive (n = 3) patients.


CONCLUSIONS
In patient villous atrophy diseases, plasma citrulline concentration may prove to be a simple and reliable marker of reduced enterocyte mass.
Crenn
Pascal
P
Department of Hepagastroenterology and Nutrion Support, Hópital Lariboisière, Paris, France. crenn@lrb.ap-hop-paris.fr
Vahedi
Kouroche
K
Lavergne-Slove
Anne
A
Cynober
Luc
L
Matuchansky
Claude
C
Messing
Bernard
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000596:Amino Acids / Q000097:blood; D001284:Atrophy; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers; D002446:Celiac Disease / Q000097:blood* / Q000178:diet therapy / Q000473:pathology*; D002956:Citrulline / Q000097:blood*; D004032:Diet; D020895:Enterocytes / Q000473:pathology*; D005260:Female; D005983:Glutens / Q000008:administration & dosage; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D000596:Amino Acids; D001323:Autoantibodies; D015415:Biomarkers; D002956:Citrulline; D005983:Glutens